Delivering precision medicine for glioma

The NCRI Brain Group’s “Delivering precision medicine for glioma” Working Group sets out to achieve Priority 3 of the NCRI Brain Group Strategic Priorities: To develop an innovative research trial to improve outcomes for brain tumour patients with unmet needs. 

This Working Group will design a study for recurrent glioblastoma patients that will define the relative roles of surgery, radiotherapy, chemotherapy and palliative care and will consider innovative study design, tissue biobanking, tumour sequencing and combination therapies.

You can see the full list of strategic priorities for the NCRI Brain Group here. 

Working Group members

Mr Richard Mair

Chair

Mr Richard Mair is Assistant Professor in Neurosurgical Oncology at th ...

Mr Richard Mair

Chair

Mr Richard Mair is Assistant Professor in Neurosurgical Oncology at the University of Cambridge and an Honorary Consultant Neurosurgeon at Addenbrooke’s Hospital. 

His lab group employ novel imaging and genomics techniques to try and understand brain cancer evolution and how this relates to interactions between intrinsic cancer cell mechanisms and the brain microenvironment. 

His clinical interest is in the surgical management of brain cancer. He undertakes a weekly operating list and is one of four dedicated neurosurgical oncology consultants that cover East Anglia. He leads the Minderoo Precision Brain Tumour Programme and the ICARUS biorepository in Cambridge. 

Dr Fiona Collinson

Deputy Chair

Dr Fiona Collinson is currently working as clinical director of  the Leeds Clinical Trials resea ...

Dr Fiona Collinson

Deputy Chair

Dr Fiona Collinson is currently working as clinical director of  the Leeds Clinical Trials research Unit and as a medical oncologist, working primarily in GI cancers and the early phase unit, and with a developing interest in brain tumours.

Dr Collinson has extensive experience through my CTU role in the development, design and delivery of phase 0-3 cancer clinical trials in both systemic therapies and RT-drug combinations. More recently, her role has been more focused on earlier phase clinical trials.

As a medical oncologist, Dr Collinson is one of a small number of people with a major interest in brain tumours. This is demonstrated by her key role in phase 0 (ReoBrain), 1 (ReoGlio) and II (Aristocrat) GBM trials and as PI on a number of commercial molecularly targeted therapies.

Dr Caroline Dobeson

Early Career Researcher (ECR) Lead

Dr Caroline Dobeson is a clinical oncology registrar at the Northern Centre for Cancer Care in Ne ...

Dr Caroline Dobeson

Early Career Researcher (ECR) Lead

Dr Caroline Dobeson is a clinical oncology registrar at the Northern Centre for Cancer Care in Newcastle upon Tyne, with a special interest in neuro-oncology. She is currently undertaking a clinical research fellowship in neuro-oncology and is a previous chair of NOTCH (National Oncology Trainees’ Collaborative for Healthcare Research).

More from NCRI